Disc Medicine, Inc. (IRON)
NASDAQ: IRON · Real-Time Price · USD
67.26
-1.59 (-2.31%)
At close: Apr 28, 2026, 4:00 PM EDT
65.92
-1.34 (-1.99%)
After-hours: Apr 28, 2026, 7:59 PM EDT
Disc Medicine Stock Forecast
Stock Price Forecast
The 11 analysts with 12-month price forecasts for Disc Medicine stock have an average target of 103.18, with a low estimate of 79 and a high estimate of 125. The average target predicts an increase of 53.40% from the current stock price of 67.26.
Analyst Consensus: Strong Buy
* Price targets were last updated on Mar 2, 2026.
Analyst Ratings
The average analyst rating for Disc Medicine stock from 11 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 6 | 6 | 5 | 5 | 5 |
| Buy | 6 | 7 | 7 | 8 | 8 | 6 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 12 | 13 | 13 | 13 | 13 | 11 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wells Fargo | Wells Fargo | Buy Maintains $78 → $79 | Buy | Maintains | $78 → $79 | +17.45% | Mar 2, 2026 |
| Truist Securities | Truist Securities | Strong Buy Maintains $114 → $83 | Strong Buy | Maintains | $114 → $83 | +23.40% | Feb 27, 2026 |
| Stifel | Stifel | Strong Buy Maintains $125 → $110 | Strong Buy | Maintains | $125 → $110 | +63.54% | Feb 17, 2026 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Maintains $153 → $125 | Buy | Maintains | $153 → $125 | +85.85% | Feb 17, 2026 |
| BMO Capital | BMO Capital | Buy Maintains $120 → $100 | Buy | Maintains | $120 → $100 | +48.68% | Feb 17, 2026 |
Financial Forecast
Revenue This Year
7.20M
Revenue Next Year
27.62M
from 7.20M
Increased by 283.52%
EPS This Year
-7.30
from -6.01
EPS Next Year
-7.70
from -7.30
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 74.1M | 56.5M | ||||||
| Avg | 7.2M | 27.6M | ||||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | 684.3% | ||||||
| Avg | - | 283.5% | ||||||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -6.59 | -6.14 | ||||||
| Avg | -7.30 | -7.70 | ||||||
| Low | -8.38 | -8.84 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.